Aripiprazole Lauroxil

Introduction Overview

Generic Name

aripiprazole lauroxil

Brand Name

Abilify Maintena

Dosage Form

extended-release intramuscular injection suspension

Drug Class

atypical antipsychotics

Pharmacokinetics

Absorption

After intramuscular injection of Abilify Maintena, aripiprazole lauroxil undergoes slow, gradual hydrolysis to release aripiprazole; peak plasma concentrations occur approximately 5 to 7 days post-injection, with sustained therapeutic levels maintained for up to a month. The absorption is rate-limited by the dissolution of the depot formulation at the injection site, providing a controlled release over extended periods. Factors such as blood flow at the injection site and muscle mass can influence absorption, but overall, the formulation ensures steady systemic exposure without the peaks and troughs seen with oral dosing.

Distribution

Aripiprazole demonstrates extensive tissue distribution with a volume of distribution approximating 4.9 L/kg, indicating wide dissemination into body compartments including the brain. Binding to plasma proteins is high, around 99%, mainly to albumin, which affects its free plasma concentrations and potential drug interactions. The ability of aripiprazole to cross the blood-brain barrier underlies its therapeutic efficacy in central nervous system disorders. Abilify Maintena’s slow-release properties maintain sustained plasma and brain concentrations over the dosage interval.

Metabolism

Aripiprazole is primarily metabolized in the liver by cytochrome P450 enzymes CYP3A4 and CYP2D6 via N-dealkylation and hydroxylation to form active metabolites, such as dehydro-aripiprazole, which contribute to the drug’s overall pharmacologic activity. Aripiprazole lauroxil itself is a prodrug that is enzymatically converted to aripiprazole via hydrolysis after absorption. The metabolic pathways may be affected by genetic polymorphisms (particularly CYP2D6 genotype), drug-drug interactions (including with CYP3A4 inducers/inhibitors), and hepatic function status, which influence plasma levels and clinical response.

Elimination

Elimination of aripiprazole occurs mainly via hepatic metabolism followed by biliary and renal excretion of metabolites. The terminal elimination half-life of aripiprazole after Abilify Maintena injection is approximately 30 to 46 days, reflecting the delayed release from the intramuscular depot and prolonged systemic clearance. Around 25% of the drug is excreted unchanged in urine and feces combined. Steady-state plasma concentrations are typically reached after 4 monthly injections. Elimination kinetics necessitate careful dose adjustments and monitoring in patients with hepatic impairment.

Dosage Forms

Adults

Abilify Maintena is supplied as a sterile aqueous extended-release intramuscular suspension for injection. The injection is administered once monthly, at doses ranging from 300 mg to 400 mg intramuscularly (either in the deltoid or gluteal muscle). The initial dosing regimen requires a one-time 400 mg IM injection plus oral aripiprazole supplementation (10 to 20 mg daily) for 14 days to maintain therapeutic plasma levels during drug release onset. Maintenace dosing is administered every 26 to 28 days thereafter. If patients experience adverse reactions at 400 mg, dose reduction to 300 mg monthly may be considered under clinical guidance.

Adolescents

Safety and efficacy in adolescent populations (under 18 years) have not been established; therefore, Abilify Maintena is not approved for use in pediatric or adolescent patients. Dosing strategies for this group require cautious clinical evaluation due to lack of data and potential different pharmacokinetic and pharmacodynamic profiles.

Special Populations

In elderly patients, particularly those with dementia-related psychosis, Abilify Maintena carries an increased risk of mortality and is contraindicated. Dose adjustments may be required for patients with hepatic impairment due to reduced metabolism of aripiprazole, although specific recommendations are limited due to insufficient data. No dosage adjustments are necessary for patients with mild to moderate renal impairment since renal excretion of unchanged drug is minimal. For patients with prior tolerance to oral aripiprazole treatment, Abilify Maintena can be initiated safely; oral supplementation protocols are essential in patients who have not been previously stabilized on aripiprazole. Injection site selection (deltoid vs. gluteal muscle) depends on patient and clinical judgement.

Mechanism Of Action

Abilify Maintena contains aripiprazole lauroxil, a prodrug of aripiprazole, an atypical antipsychotic agent that exerts its therapeutic effects primarily through partial agonism at dopamine D2 and serotonin 5-HT1A receptors, and antagonism at serotonin 5-HT2A receptors. This unique receptor profile modulates dopaminergic and serotonergic neurotransmission, balancing dopamine activity in various brain regions implicated in psychosis and mood regulation. By acting as a partial agonist at D2 receptors, aripiprazole stabilizes dopamine signaling, reducing excessive dopaminergic activity in mesolimbic pathways associated with positive symptoms of schizophrenia while enhancing dopamine function in mesocortical areas to alleviate negative and cognitive symptoms. Additionally, the partial agonism at 5-HT1A receptors confers anxiolytic and antidepressant effects, whereas 5-HT2A antagonism reduces extrapyramidal side effects common to typical antipsychotics. The gradual release of aripiprazole from Abilify Maintena’s injectable suspension ensures prolonged receptor engagement and steady therapeutic plasma concentrations, improving adherence and treatment efficacy. Clinical studies demonstrate that this pharmacodynamic action leads to significant improvement in manic, mixed, and psychotic symptoms, contributing to the long-term stabilization of schizophrenia and bipolar I disorder. Compared to other atypical antipsychotics, aripiprazole's mechanism uniquely balances receptor activity to minimize side effects such as sedation and weight gain, increasing tolerability among patients.

Pharmacological Actions

Partial agonism at dopamine D2 receptors leading to modulation of dopaminergic neurotransmission
Partial agonism at serotonin 5-HT1A receptors providing anxiolytic and antidepressant properties
Antagonism at serotonin 5-HT2A receptors reducing extrapyramidal symptoms and enhancing antipsychotic efficacy
Extended-release intramuscular depot formulation releasing aripiprazole gradually over one month
Stabilization of dopamine and serotonin pathways implicated in schizophrenia and bipolar disorder
Reduction of positive symptoms such as hallucinations and delusions
Improvement of negative symptoms including emotional withdrawal and apathy
Mood stabilization in bipolar I disorder to prevent manic and mixed episodes
Low propensity for inducing extrapyramidal side effects compared to typical antipsychotics
Minimal sedative effects compared to other agents in the class
Decreased risk of prolactin elevation due to partial dopamine receptor agonism
Potential influence on impulse control via dopaminergic and serotonergic mechanisms
Maintenance of steady plasma and CNS drug concentrations enhancing adherence

Therapeutic Clinical Uses

Treatment and maintenance therapy of schizophrenia in adults
Management of bipolar I disorder including manic and mixed episodes
Monotherapy or adjunctive therapy with other aripiprazole formulations
Prevention of relapse in stabilized patients with schizophrenia or bipolar I disorder
Long-term symptom control to reduce frequency and severity of mood episodes
Management of psychotic symptoms linked to dopamine and serotonin imbalance
Treatment option for patients with adherence challenges due to once-monthly injectable dosing
Alternative to oral antipsychotics for sustained drug delivery
Improvement in quality of life by stabilizing mood and cognitive functions
Reduction of hospitalizations related to psychotic and mood symptoms

Side Or Adverse Effects

Weight gain observed in approximately 17% of patients
Akathisia (inability to remain still) reported in about 11%
Constipation occurring in around 10% of patients
Injection site pain in approximately 5%
Sedation or somnolence in about 5%
Dry mouth experienced by around 4%
Upper respiratory tract infections around 4% incidence
Weight loss in some patients (~4%)
Dizziness reported in 4%
Gastrointestinal symptoms including diarrhea and vomiting (~3%)
Muscle and joint pain in 3%
Tremors or involuntary movements (~3%)
Abdominal discomfort and nasal congestion in smaller percentages (2%)
Potential serious side effects include tardive dyskinesia with long-term or high-dose use
Rare but serious neuroleptic malignant syndrome symptoms
Increased sexual or gambling urges associated with impulse control issues
Elevations in blood sugar leading to hyperglycemia or potential diabetes
Allergic reactions including anaphylaxis, hives, and swelling
Low blood cell counts causing infections, fatigue, or bleeding
Orthostatic hypotension leading to dizziness or falls

Precautions

Do not use in patients with known hypersensitivity to aripiprazole or formulation components
Monitor for tardive dyskinesia signs, especially in women and elderly
Cautious use in patients with cardiovascular disease, history of stroke or arrhythmias
Regular monitoring of blood sugar and lipids due to metabolic risks
Avoid abrupt discontinuation to prevent symptom relapse
Use with caution in patients with seizure disorders
Assess injection site before administration to prevent local complications
Careful dose adjustment in hepatic impairment patients
Risk of orthostatic hypotension; counsel patients on positional changes
Avoid alcohol consumption during treatment due to risk of sedation and hypotension
Pregnancy registry enrollment recommended for exposed pregnant women
Caution in patients with low white blood cell counts or immunosuppression
Evaluate risk-benefit in elderly patients with dementia-related psychosis
Monitor for impulse control disorders such as gambling or hypersexuality
Educate patients on recognizing signs of severe adverse reactions

Warnings

Increased risk of mortality in elderly patients with dementia-related psychosis; not approved for this use
Potential for tardive dyskinesia, which may be irreversible
Risk of neuroleptic malignant syndrome, a potentially fatal syndrome
May cause hyperglycemia and diabetes mellitus; monitor blood glucose
Suicidal thoughts and behaviors possible; monitor mood and behavior
Orthostatic hypotension leading to dizziness and falls especially in elderly
Seizure risk increased; use caution in patients with seizure history
Potential for severe allergic reactions, including anaphylaxis
Injection site reactions possible; rotate injection site
Risk of impulse control disorders including pathological gambling and compulsive behaviors
Do not use in patients with a known allergy to aripiprazole lauroxil
Avoid use in patients with dehydration or electrolyte imbalance
Use caution with co-administration of CYP3A4 and CYP2D6 inhibitors

Contraindications

Known hypersensitivity to aripiprazole, aripiprazole lauroxil, or formulation excipients
Use in elderly patients with dementia-related psychosis due to increased mortality risk
Patients with severe hypersensitivity or anaphylactic reactions to aripiprazole
Concomitant use of similar dopamine partial agonists or antagonists without medical supervision
Situations where intramuscular injection is contraindicated or poorly tolerated
Patients with a history of neuroleptic malignant syndrome without close clinical supervision
Known QT interval prolongation disorders warrant cautious use, though not strict contraindication

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase aripiprazole plasma levels; consider dose adjustment
Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can elevate aripiprazole exposure
CYP3A4 inducers (e.g., carbamazepine) may decrease aripiprazole concentrations reducing efficacy
Concurrent use with other CNS depressants (e.g., benzodiazepines, alcohol) can enhance sedation and hypotension risk
Drugs that prolong QT interval may increase cardiac arrhythmia risk
Medications for hypertension may have additive hypotensive effects
Interactions with anticholinergic agents could exacerbate side effects such as constipation or tachycardia
Caution with opioids due to increased sedation and respiratory depression potential
Drugs affecting dopaminergic neurotransmission may interact pharmacodynamically
Many over-the-counter cold and allergy medications may potentiate side effects
Monitor patients closely when combining with other psychotropics
Avoid abrupt withdrawal or initiation of interacting agents without healthcare consultation
Vitamin and herbal supplements (e.g., St. John's Wort) may alter metabolism

Preparations Of The Drug

Extended-release injectable suspension for intramuscular use
Available in single-dose vials of 300 mg and 400 mg formulations
Suspension prepared prior to administration as per manufacturer's instructions
Formulation contains aripiprazole monohydrate as active ingredient
Inactive ingredients include carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate, and sodium hydroxide
Injection intended for deep intramuscular injection either in the deltoid or gluteal muscle
Supplied as sterile, preservative-free aqueous suspension
Requires administration by healthcare professional once monthly
Not intended for intravenous or subcutaneous use